{"title":"升阳益胃汤为主干预治疗腹泻型肠易激综合征的meta分析","authors":"T. Zhu, Hui Ding, Leilei Zheng","doi":"10.25236/FMSR.2021.030506","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: To investigate the efficacy and safety of Shengyang Yiwei Decoction as the main intervention in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), and to provide evidence for its clinical application. METHODS: Randomized controlled trials (RCTs) of Shengyang Yiwei Decoction in The treatment of IBS-D were searched from CNKI, Wanfang database, PubMed, The Cochrane Library and VIP database from the establishment of these databases to June 10, 2020. The Cochrane risk bias tool in the Cochrane manual was used to evaluate the literature quality. Meta-analysis was performed using RevMan5.3 software. Results: A total of 16 RCTs were included, involving 1244 patients. Meta-analysis results showed that: Total effective rate (N =1204, OR=3.38, 95%CI [2.43, 4.71], P","PeriodicalId":129141,"journal":{"name":"Frontiers in Medical Science Research","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meta-analysis of Shengyang Yiwei Decoction as The Main Intervention in The Treatment of Diarrhea-Predominant Irritable Bowel Syndrome\",\"authors\":\"T. Zhu, Hui Ding, Leilei Zheng\",\"doi\":\"10.25236/FMSR.2021.030506\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE: To investigate the efficacy and safety of Shengyang Yiwei Decoction as the main intervention in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), and to provide evidence for its clinical application. METHODS: Randomized controlled trials (RCTs) of Shengyang Yiwei Decoction in The treatment of IBS-D were searched from CNKI, Wanfang database, PubMed, The Cochrane Library and VIP database from the establishment of these databases to June 10, 2020. The Cochrane risk bias tool in the Cochrane manual was used to evaluate the literature quality. Meta-analysis was performed using RevMan5.3 software. Results: A total of 16 RCTs were included, involving 1244 patients. Meta-analysis results showed that: Total effective rate (N =1204, OR=3.38, 95%CI [2.43, 4.71], P\",\"PeriodicalId\":129141,\"journal\":{\"name\":\"Frontiers in Medical Science Research\",\"volume\":\"34 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medical Science Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25236/FMSR.2021.030506\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medical Science Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25236/FMSR.2021.030506","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨升阳益胃汤为主干预治疗腹泻型肠易激综合征(IBS-D)的疗效和安全性，为其临床应用提供依据。方法:从中国知网(CNKI)、万方数据库、PubMed、The Cochrane Library和VIP数据库建立至2020年6月10日检索升阳益胃汤治疗IBS-D的随机对照试验(RCTs)。采用Cochrane手册中的Cochrane风险偏倚工具评价文献质量。采用RevMan5.3软件进行meta分析。结果:共纳入16项rct, 1244例患者。meta分析结果显示:总有效率(N =1204, OR=3.38, 95%CI [2.43, 4.71]， P
Meta-analysis of Shengyang Yiwei Decoction as The Main Intervention in The Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
OBJECTIVE: To investigate the efficacy and safety of Shengyang Yiwei Decoction as the main intervention in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), and to provide evidence for its clinical application. METHODS: Randomized controlled trials (RCTs) of Shengyang Yiwei Decoction in The treatment of IBS-D were searched from CNKI, Wanfang database, PubMed, The Cochrane Library and VIP database from the establishment of these databases to June 10, 2020. The Cochrane risk bias tool in the Cochrane manual was used to evaluate the literature quality. Meta-analysis was performed using RevMan5.3 software. Results: A total of 16 RCTs were included, involving 1244 patients. Meta-analysis results showed that: Total effective rate (N =1204, OR=3.38, 95%CI [2.43, 4.71], P
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
